Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694570 | 0.93 | F10 (0.62) | F10 | |
| SCHEMBL6698444 | 0.89 | F10 (0.62) | F10 | |
| SCHEMBL6694593 | 0.84 | KCNH2 (0.61) | F10KCNH2HTTTSHRNPSR1 | |
| SCHEMBL6697986 | 0.83 | F10 (0.63) | F10KCNH2 | |
| SCHEMBL6700838 | 0.78 | F10 (0.57) | F10KCNH2 | |
| SCHEMBL6698311 | 0.78 | F10 (0.57) | F10KCNH2 | |
| SCHEMBL6693138 | 0.78 | F10 (0.56) | F10KCNH2 | |
| SCHEMBL6693135 | 0.78 | F10 (0.56) | F10KCNH2 | |
| SCHEMBL6700863 | 0.77 | F10 (0.57) | F10 | |
| SCHEMBL6693144 | 0.76 | F10 (0.56) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072860-A1 | Piperazin-2-one amides as inhibitors of factor xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-15 | — | — | US | disclosed |
| EP-1322643-A1 | PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR XA | Millennium Pharmaceuticals, Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002026734-A1 | PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072860-A1 | Piperazin-2-one amides as inhibitors of factor xa | F2, TFPI, TFPI2 | F10 12/4885KCNH2 2157/4885HTT 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.